Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Healthcare (Basel, Switzerland)|December 30, 2025
Substance-Specific Treatment Responses and Resistance Patterns in Induced Psychoses: A Scoping Review of Antipsychotic EfficacyValerio Ricci, Stefania Chiappini, Giovanni Martinotti, et al.
Psychiatry Research|April 19, 2025
Cannabis use and psychotic-like experiences: A systematic review of biological vulnerability, potency effects, and clinical trajectoriesValerio Ricci, Stefania Chiappini, Giovanni Martinotti, et al.
The International Journal of Neuropsychopharmacology|February 6, 2019
An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug ReactionsFabrizio Schifano, Stefania Chiappini, John M Corkery, et al.
Brain Sciences|April 26, 2018
Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic ReviewFabrizio Schifano, Stefania Chiappini, John M Corkery, et al.
Frontiers in Pharmacology|February 19, 2019
Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting SystemsFabrizio Schifano, Stefania Chiappini, John Martin Corkery, et al.
Journal of Psychopharmacology (Oxford, England)|January 11, 2021
Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reportsStefania Chiappini, Fabrizio Schifano, John Martin Corkery, et al.
Brain Sciences|February 22, 2020
Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance DatabaseStefania Chiappini, Fabrizio Schifano, John Martin Corkery, et al.
Basic & Clinical Pharmacology & Toxicology|March 3, 2018
β-2 Agonists as Misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency Pharmacovigilance Database ReportsGiulia Milano, Stefania Chiappini, Francesca Mattioli, et al.
Neurotoxicology|August 15, 2019
Cannabidiol (CBD) use in psychiatric disorders: A systematic reviewStefania Bonaccorso, Angelo Ricciardi, Caroline Zangani, et al.
Lower Urinary Tract Symptoms|October 10, 2020
Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reportsNicolo' Schifano, Stefania Chiappini, Fabio Castiglione, et al.
Pageof 9